Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.10. | Milestone Pharmaceuticals maintains Buy rating from TD Cowen | 2 | Investing.com | ||
14.10. | Wainwright maintains Buy rating on Milestone Pharma stock | 1 | Investing.com | ||
06.09. | Milestone Pharmaceuticals Inc.: Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China | 89 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
04.09. | Milestone Pharmaceuticals welcomes new board member Joseph Papa | 1 | Investing.com | ||
04.09. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.09. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors | 1 | GlobeNewswire (USA) | ||
09.08. | Milestone Pharmaceuticals GAAP EPS of -$0.14 | 1 | Seeking Alpha | ||
09.08. | Milestone Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary | 1 | Reuters | ||
08.08. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.08. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 80 | GlobeNewswire (Europe) | - NDA for CARDAMYST in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 - Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 - Stuart Duty and Andrew Saik Appointed... ► Artikel lesen | |
08.08. | Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
15.07. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.06. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals to Host KOL Event for Investors "Learnings from the Field: Expert Perspectives on PSVT in the Community Setting" on June 20, 2024 | 1 | GlobeNewswire (USA) | ||
31.05. | Milestone Pharmaceuticals Inc.: Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference | 1 | GlobeNewswire (USA) | ||
29.05. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | - | SEC Filings | ||
29.05. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST | 208 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
13.05. | Milestone Pharmaceuticals GAAP EPS of -$0.21 beats by $0.05 | 1 | Seeking Alpha | ||
13.05. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | - | SEC Filings | ||
13.05. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 165 | GlobeNewswire (Europe) | - NDA for etripamil in PSVT resubmitted in 1Q 2024- Cash resources as of March 31, 2024 expected to fund operations into 2026- Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR... ► Artikel lesen | |
13.05. | Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 25,965 | +0,15 % | Ihre wichtigsten Termine: Frische Q3-Zahlen von: Alphabet, Visa, PayPal, McDonald's, Pfizer und Lufthansa | © Foto: Rolf Vennenbernd/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:50... ► Artikel lesen | |
GILEAD SCIENCES | 82,55 | -0,07 % | Gilead Sciences Aktie: Positive Wellen schlagen! | ||
MERCK & CO | 94,10 | -0,11 % | Merck & Co: Ergebnisprognose kassiert - Probleme in China | Am Donnerstag hat neben vielen anderen Unternehmen auch der US-amerikanische Pharma-Riese Merck & Co die Zahlen zum abgelaufenen dritten Quartal vorgelegt. Diese sind gemischt ausgefallen. Während sich... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 436,60 | +0,47 % | Vertex Aktie: Was können Sie jetzt erwarten? | Die Vertex Pharmaceuticals-Aktie verzeichnete am 31. Oktober 2024 einen leichten Kursanstieg von 1,84% auf 438,53 Euro. Trotz der positiven Kursentwicklung in den letzten Wochen, mit einem Zuwachs von... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 10,675 | +0,95 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema | - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline - - DURAVYU 2.7mg demonstrated an early and sustained anatomical improvement... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 10,200 | -2,86 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Global Angioedema Forum | Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts... ► Artikel lesen | |
ASSEMBLY BIOSCIENCES | 16,400 | +4,79 % | Assembly Biosciences - Herpes-Wirkstoff übertrifft Erwartungen | Mein diesjähriger Top-Favorit Assembly Biosciences (WKN: A402CB) präsentierte gestern herausragende Studiendaten seines Wirkstoffkandidaten ABI-5366 zur Behandlung von wiederkehrendem Genitalherpes.... ► Artikel lesen | |
NEWRON PHARMACEUTICALS | 8,870 | +3,50 % | Newron SpA Aktie: Stabile Performance trotz Herausforderungen | ||
OPKO HEALTH | 1,370 | -2,66 % | OPKO Health, Inc.: OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 | ||
LIGAND PHARMACEUTICALS | 98,00 | -2,97 % | Ligand Pharmaceuticals Inc Q2 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Ligand Pharmaceuticals Inc (LGND):Earnings: -$51.911 million in Q2 vs. $2.290 million in the same period last year.
EPS: -$2.88... ► Artikel lesen | |
ALTIMMUNE | 6,315 | +1,58 % | Altimmune, Inc: Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) | IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025 End-of-Phase 2 Meeting for the obesity program... ► Artikel lesen | |
EXSCIENTIA | 4,480 | -0,88 % | Exscientia plc: Exscientia erreicht Meilensteine für zwei Programme im Rahmen der Zusammenarbeit mit Sanofi | Beide Programme demonstrieren die Fähigkeit von Exscientia, hochdifferenzierte, potenziell erstklassige Moleküle zu entwerfen Exscientia erhält für das Erreichen dieser Meilensteine 15 Millionen... ► Artikel lesen | |
JAZZ PHARMACEUTICALS | 101,75 | -0,15 % | Jazz Pharmaceuticals plc (JAZZ): Among the Best Stocks to Buy for High Returns in 2024 | ||
ROYALTY PHARMA | 25,020 | 0,00 % | Kurs verdoppelt!: BRAIN Biotech: Millionen-Deal mit Royalty Pharma sorgt für Kurs-Explosion | © Foto: Sebastian Kahnert/dpaDas Biotech-Perle aus dem hessischen Zwingenberg verkauft die Rechte an seinem Wirkstoff Deucrictibant und erhält dafür Zahlungen, die die eigene Marktkapitalisierung um... ► Artikel lesen | |
ROCKET LAB USA | 10,440 | -0,76 % | Could Rocket Lab Be a Millionaire-Maker Stock in the Trillion-Dollar Space Industry? |